

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

ZIMMERMANN ET AL.

Examiner: Bernhardt, Emily B.

APPLICATION NO: 09/463,097

FILED: JANUARY 18, 2000

FOR: CRYSTAL MODIFICATION OF AN N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS USE

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
OCT 25 2004  
TECHNOLOGY CENTER 2809

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(b)4.

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

  
George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824  
Date: October 21, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ZIMMERMANN ET AL.

APPLICATION NO: 09/463,097

FILED: JANUARY 18, 2000

FOR: CRYSTAL MODIFICATION OF AN N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS USE

Art Unit: 1624

Examiner: Bernhardt, Emily B.

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(b)4.

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

  
George R. Dohmann  
Attorney for Applicants  
Reg. No. 33,593

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7824  
Date: October 21, 2004